Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-24
2006-10-24
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S278000, C544S279000, C544S280000, C546S272400, C546S273100, C546S269100, C546S286000, C546S290000, C546S304000, C546S314000, C546S329000, C546S339000, C546S345000, C546S348000, C514S265100, C514S339000, C514S344000, C514S345000, C514S319000, C514S350000, C514S351000, C514S354000, C514S357000
Reexamination Certificate
active
07125880
ABSTRACT:
Corticotropin-releasing factor (CRF) antagonists having the formulaewherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16and R17are as defined in the application, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment disorders including CNS and stress-related disorders.
REFERENCES:
patent: 3637720 (1972-01-01), Nishiyama
patent: 4018895 (1977-04-01), Molloy et al.
patent: 4605642 (1986-08-01), Rivier et al.
patent: 4655824 (1987-04-01), Mengel et al.
patent: 4786317 (1988-11-01), Mengel et al.
patent: 4839353 (1989-06-01), Hosoi et al.
patent: 4925947 (1990-05-01), Cartwright
patent: 5032168 (1991-07-01), Turner
patent: 5063245 (1991-11-01), Abreu et al.
patent: 5691364 (1997-11-01), Buckman et al.
patent: 5719185 (1998-02-01), Bountra et al.
patent: 6384039 (2002-05-01), Fossa
patent: 0154538 (1982-03-01), None
patent: 3145287 (1983-05-01), None
patent: 0315916 (1989-05-01), None
patent: 0385720 (1990-09-01), None
patent: 0475411 (1992-03-01), None
patent: 0482804 (1997-01-01), None
patent: 0773023 (1997-05-01), None
patent: 0951906 (1999-10-01), None
patent: 1040831 (2000-04-01), None
patent: 1059100 (2000-12-01), None
patent: 7900094 (1979-03-01), None
patent: 94/13643 (1994-06-01), None
patent: 94/13644 (1994-06-01), None
patent: 94/13661 (1994-06-01), None
patent: 94/13676 (1994-06-01), None
patent: 94/13677 (1994-06-01), None
patent: WO 9413676 (1994-06-01), None
patent: 95/34563 (1995-03-01), None
patent: 9510506 (1995-04-01), None
patent: 95/33750 (1995-12-01), None
patent: 9533750 (1995-12-01), None
patent: WO 95/33750 (1995-12-01), None
Schaefer et al., “Synthesis and reactions of 2-amino-1-aryl-5-oxo-delta-2-pyrroline-3-carbonitriles”, Abstract of Monatash. Chem. 120(4), pp 315-322, 1989.
Hardman, J.G., Editor-in-Chief, “Goodman & Gilman's The Pharmacological Basis of Therapeutics” 9thEdition, pp. 431-446, 1996.
Chalmers, D. T., et al., Corticotrophin-releasing factors molecular biology to drug design, Trends in Pharmacological Sciences, (1996), vol. 17, pp. 166-172.
Cassey, A. L., et al. “Pyridines & Pyridinium Salts from Cyanoacetamides” Australian Journal of Chem. (1976), 29. p 1039-50.
Owens, et al., “Physiology and Pharmacology of Corticotropin-releasing factor”, Pharm. Rev., (1991), vol. 43, pp. 425-473.
Fujikakwa, K., et al. “Herbicidal activities of phenoxypyridines”. Chemical Abstract, (1970(), Abstract No. 11080v.
Fujikawa, K., et al. “Studies on Herbicidal Activities of Phenoxypyridines”. Arg. Biol. Chemical, (1970), vol. 34, No. 1 p. 68-79.
DeSouza, E.B., “Corticotropin-releasing Factor Receptors Physiology, Pharmacology, Biochemistry & Role in Central Nervous Systems & Immune Disorders.”, (1995), vol. 20, No. 8, pp. 789-819.
Fackelmann, K.A. & Raloff, J. “Psychological Street Linked to Cancer”, Science News, (Sep. 25, 1993), vol. 144, p. 196.
Lyons, M.K., et al., “Corticotropin releasing factor antagonist reduces ischemic hippocampal neuronal injury”, Brain Research, (1991), vol. 545, Issue 1-2, pp. 339-342.
Stratakis, C.A.& Chrousos, G. P., “Hypothalamic Homones, GnRH, TRH, CHRH, SRIF, CRH, & Dopaime, Endocrinology ” Basic & Clinical Principles, (1997), pp. 185-209 (Humana Press, Tofowa, NJ, 1997).
Strijbos, P. J. L. M., et al. Brain Research, vol. 656, (1991), pp. 405-408.
Robins, M.J., et al., Can. J. Chem. (1977), vol. 55, pp. 1252-1259.
Hormonal Responses of Metoclopramide- Treated Subjects experiencing Nausea or emesis During Parabolic Flight, Aviation, Space and Environmental Medicine, Sep. 1987- Kohl.
Delta Sleep-Inducing Peptide Response to Human Corticotropin-Releasing Hormone (CRH) in Major Depressive Disodr, 1998 Soc. Biol. Physchiatry—Lesch, Widerlov, Ekman, Laux, Schulte, Pfuller,Beckman.
Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders, Endocrinology and Metabolism Clinics of N.A. 31 (2002) 15-36—Vgontzas, Chrousos.
Antidepressant-like effects of CP-154,526, a selective CRF, receptor antagonist, European Journal of Pharmacology 323 (1997) 21-26, Mansback, Brooks, Chen.
CP-154,526: A potent& selective nonpeptide antagonist of corticotropin releasing fctr receptors, Proc. Natl Acad Sci.vol. 93, pp 10477-10482, Sep. 1996 Pharmacology—Shultz, Mansbach, Sprouse, Braselton, Collins, Corman, Dunaiskis, Faraci, Schmidt, Seeger, Seymour, Tingley, Winston, Chen, Heym.
Corticotropin-releasing hormone microinfusion in central anygdale diminishes a cardiac parasy mpathetic otflow undr stress-free conditns, Brain Research 625(1993)219-227pp27-35- Bohus, Koolhaas.
Interactions between Testicular Serotoninergic, Catecholaminergic, and Corticotropin-Releasing Hormone Systems Modulating cAMP and Testosterone Production in the Golden Hamster, Neuroendocrinology 2002:76:35-46- Frungieri, Zitta, Pignataro, Gonzalez-Calvar, Calandra.
The Role of the CRH Type 1 Rcptr in Autonomic Responses to Corticotropin-Releasing Hormone in the Rat,Neuropsychopharmacology 2000-vol. 22,No. 4- Nijsen,Croiset,Stam,Bruijnzeel,Diamant,Wied, Wiegant.
Dble-blnd, randomized trl for the cntl of delayed emesis in pnts receiving cisplatin: Comparison of placebo vs. adrenocorticotropic hormone (ACTH), Anls of Oncology3:481-485 1992- Passalacque, Cocconi, Bella,Monici,Michiara,Bandini,Bacchi.
Dble-Blnd, Multicenter, Randomized Trial to Cmpre the Effect of 2 Dses of Adrenocorticotropic Hormone Vs Placebo in Controlling Delayed Emesis After High-Dose Cisplatin in Adult Patients with Cancer, Journal of Clinical Oncology, vol. 15, No. 6(Jun.) 1997, pp 2467-2473—Passalacqua, Cocconi, Caminiti, Silingordi, Bella, Bichisao, Michiara, Malavasi, Donati, Di Costanzo, Rocca, Sarra, Scaglione, Fraschini.
Evans, et al., J. Am. Chem. Soc. (1989) III, pp. 1063-1072—The Total Synthesis of the Isodityrosine-Derived Cyclic Tripeptides of 4949-III and K-13. Determination of the Absolute Configuration of K-13.
Williams, et al. Solvent-assisted Ullmann Ether Synthesis, Reactions of Dihydriephenols, J. Org. C hem. 32, pp. 2501-2505 (1967).
Schmidt, et al., Total Synthesis of 4924-III, a natural inhibitor of amino-peptidase B from Ehrlich Asates Carcinoma Cells, Tetra. Ltrs, 29(26) pp. 3227-3230 (1988).
Reagents for Organic Synthesis, vol. I, Fieser, et al. (1972) p. 68.
Reagents for Organic Synthesis, vol. 9, Fieser, et al. (1981) pp.125.
L.A. Fisher, Central Actions of Corticotropin-Releasing Factor on Autonomic Nervous Activity and Cardiovascular Functioning (1993) Corticotropin-Releasing Factor, CIBA Found. Symposium 172, pp. 243-257.
M.R. Brown et al., Endocrinology 111:928 (1982).
J.M. Overton et al., Journal of the Autonomic Nervous System, 35 (1991) 43-52.
M.R. Brown et al, Life sciences, vol. 30, No. 2, pp. 207-210 (1982).
L.S. Fisher et al., Endocrinology 110 (6), pp. 2222-2224 (1982).
C.L. Grosskreutz et al., Brain Research, 442 (1988) pp. 363-367.
M.R. Brown et al., Brain Research, 280 (1983) 75079.
J.M. Overton et al., Central Nervous System Effects of CRF and Angiotensis II on Cardiac Output in Conscious Rats, J. Appl. Physiol. 69(2) pp. 788-791 (1990).
H. Lehnert et al., Neuropsychobiology, 28:54-61 (1993).
A. Wiersma et al., Brain Research, 625 (1993) 219-227.
A.L. Curtis et al., Brain Res. Bulletin, vol. 31, pp. 737-744 (1993).
Abstract of E. Rohde et al., Biochemical Pharmacology, 52(6) pp. 829-833 (1996).
R.J. Valentino et al., Brain Research, 555 (1991) p. 25-34.
R.J. Valentino et al., Neuroendocrinology, 48, pp. 674-677 (1988).
T. Nakamori et al., Am. J. Physio., 265:R834-R839 (1993).
G.S. Francis et al., Circulation, 87 (Suppl. VI): V140-V148 (1993).
Chhabria et al, Heterocycles, vol. 51, No. 11, 1999.
Kamel et al, Pharmazie1990, 45 (2), 139-140.
Demina et al., Khim. Farm. Zh., 1993, 27(7), pp. 34-35 (with English summary).
Demina et al., Geterotsikl Soedin, 192 (11), pp. 1506-1508 (with English summary).
LandOfFree
Corticotropin releasing factor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Corticotropin releasing factor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Corticotropin releasing factor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3630320